Intrasphincteric botulinum toxin injection in the treatment of chagasic achalasia.
According to the WHO, 16-18 million people in Central and South America are infected by Trypanosoma cruzi. Chagasic achalasia affects between 7.1% and 10.6% of the population. The aim of this study was to evaluate the effects of Botox injections in the clinical response and esophageal function of patients with dysphagia due to chagasic achalasia. In total, 24 symptomatic patients with chagasic achalasia were randomly chosen to receive Botulinum Toxin (BT) or saline injected by endoscopy in the lower esophageal sphincter (LES). Patients were monitored with a clinical score of dysphagia and an objective assessment (esophagograms, scintillography, manometry, and nutritional assessment) for a period of 6 months. Clinical improvement of dysphagia was statistically significant (P < 0.001) in patients receiving BT when compared with the placebo. There was no significant difference in the placebo group regarding clinical score, LES basal pressure and esophageal emptying time. Esophageal emptying time in the toxin group was significantly lower than in the placebo (P=0.04) after 90 days. There were non-significant increases in esophageal emptying of 25.36% and 17.39%, respectively, at 90 and 180 days, in the BT group (P=0.266). Gender, age, and baseline LES pressure did not influence the response to BT. Our data strongly suggests that intrasphincteric injection of BT in LES is clinically effective in the treatment of chagasic achalasia.
Brant
C
C
Division of Gastroenterology, São Paulo Federal University, Brazil.
Moraes-Filho
J P P
JP
Siqueira
E
E
Nasi
A
A
Libera
E
E
Morais
M
M
Rohr
M
M
Macedo
E P
EP
Alonso
G
G
Ferrari
A P
AP
D000293:Adolescent; D000328:Adult; D000368:Aged; D018726:Anti-Dyskinesia Agents / Q000008:administration & dosage*; D001905:Botulinum Toxins / Q000008:administration & dosage*; D014355:Chagas Disease / Q000150:complications*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004931:Esophageal Achalasia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D004943:Esophagogastric Junction / Q000187:drug effects; D004945:Esophagoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D011336:Probability; D011446:Prospective Studies; D020127:Recovery of Function; D012016:Reference Values; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018726:Anti-Dyskinesia Agents; D001905:Botulinum Toxins